This review explores the potential clinical utility of genetic variation, pharmacogenetics, and risk prediction in the management of atrial fibrillation.
Answers are grounded in this paper and cite their sources.
May support personalized AF strategies; leaves open prospective validation before clinical adoption.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Lubitz et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: